Samsara's IOT short percent of float has risen 7.91% since its last report. The company recently reported that it has 10.90 million shares sold short, which is 4.64% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.3 days to cover their ...

Donald Trump's second term bears resemblance to Florida's political transformation, with key Sunshine State figures leading the charge for dramatic spending cuts and deregulation in Washington.

Teledyne Technologies's TDY short percent of float has fallen 4.55% since its last report. The company recently reported that it has 449 thousand shares sold short, which is 1.26% of all regular shares that are available for trading.

Airbnb's room night growth, revenue and adjusted EBITDA came in ahead of consensus. The company's Q1 guidance of room night and revenue growth came in at 8.5% and 4%-6%, both missing estimates.

EQS Voting Rights Announcement: LANXESS Aktiengesellschaft LANXESS Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution Dissemination of a Voting Rights Announcement transmitted by EQS News - ...

Investors with a lot of money to spend have taken a bearish stance on Rocket Lab USA RKLB. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.

Financial giants have made a conspicuous bullish move on Rivian Automotive. Our analysis of options history for Rivian Automotive RIVN revealed 14 unusual trades. Delving into the details, we found 42% of traders were bullish, while 35% showed bearish tendencies.

Deep-pocketed investors have adopted a bearish approach towards Oklo OKLO, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.

Albany International will move production from Ballo to Merone, streamlining operations and reducing costs. Affected employees will be offered transfer opportunities or separation assistance, with details to be disclosed later.

The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 vaccine sales.